Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTBNASDAQ:MTVANASDAQ:MURANASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$0.82+1.2%$0.76$0.51▼$2.08$45.39M-0.2256,512 shs34,532 shsMTVAMetaVia$0.78-1.0%$1.37$0.65▼$5.30$6.78M0.22388,605 shs59,709 shsMURAMural Oncology$2.65+1.5%$2.67$0.95▼$4.74$45.64M5.281.29 million shs266,479 shsSTTKShattuck Labs$0.84+4.3%$1.09$0.69▼$11.76$40.09M1.76380,308 shs28,181 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma+3.71%+8.72%+19.12%-17.35%-39.55%MTVAMetaVia-3.84%+7.97%-49.94%-60.05%+79,099,900.00%MURAMural Oncology+0.38%-2.97%+121.19%-31.85%-27.09%STTKShattuck Labs+0.97%+2.42%-23.78%-31.86%-92.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTBConnect Biopharma2.5983 of 5 stars3.53.00.00.01.82.50.6MTVAMetaVia2.0938 of 5 stars3.50.00.00.02.50.01.3MURAMural Oncology3.0579 of 5 stars3.35.00.00.01.71.71.3STTKShattuck Labs2.5675 of 5 stars3.42.00.00.02.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 3.00Buy$8.00875.61% UpsideMTVAMetaVia 3.00Buy$12.001,432.57% UpsideMURAMural Oncology 2.60Moderate Buy$13.00390.57% UpsideSTTKShattuck Labs 2.71Moderate Buy$7.50793.92% UpsideCurrent Analyst Ratings BreakdownLatest MTVA, MURA, CNTB, and STTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/27/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/27/2025STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/21/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/17/2025STTKShattuck LabsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/17/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$4.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$24.12M1.88N/AN/A$1.83 per share0.45MTVAMetaViaN/AN/AN/AN/A$3.44 per shareN/AMURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/ASTTKShattuck Labs$5.72M7.02N/AN/A$3.41 per share0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$59.50MN/A0.00N/AN/AN/AN/AN/AN/AMTVAMetaVia-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%5/8/2025 (Estimated)MURAMural Oncology-$207.45M-$7.58N/AN/AN/AN/A-70.10%-61.30%5/13/2025 (Estimated)STTKShattuck Labs-$87.30M-$1.49N/AN/AN/A-1,156.46%-61.92%-54.49%5/1/2025 (Estimated)Latest MTVA, MURA, CNTB, and STTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/AMURAMural Oncology-$1.68N/AN/AN/AN/AN/A5/8/2025Q1 2025MTVAMetaVia-$0.61N/AN/AN/AN/AN/A5/1/2025Q4 2024STTKShattuck Labs-$0.29N/AN/AN/AN/AN/A3/27/2025Q4 2024STTKShattuck Labs-$0.38-$0.37+$0.01-$0.37$1.00 millionN/A3/11/2025Q4MURAMural Oncology-$1.96-$2.01-$0.05-$2.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect BiopharmaN/A12.04N/AMTVAMetaViaN/A2.412.41MURAMural OncologyN/A7.387.38STTKShattuck LabsN/A7.967.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%MTVAMetaVia1.37%MURAMural Oncology80.21%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%MTVAMetaVia1.05%MURAMural Oncology0.06%STTKShattuck Labs10.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11055.35 million42.77 millionOptionableMTVAMetaVia88.66 million8.53 millionN/AMURAMural Oncology11917.23 million17.01 millionOptionableSTTKShattuck Labs10047.90 million42.73 millionOptionableMTVA, MURA, CNTB, and STTK HeadlinesRecent News About These CompaniesShattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comBrokers Issue Forecasts for Shattuck Labs Q1 EarningsMarch 31, 2025 | marketbeat.comShattuck Labs Full Year 2024 Earnings: Misses ExpectationsMarch 29, 2025 | uk.finance.yahoo.comShattuck Labs reports Q4 EPS (37c), consensus (32c)March 29, 2025 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)March 29, 2025 | markets.businessinsider.comShattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | finanznachrichten.deShattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationMarch 18, 2025 | msn.comShattuck Labs initiated with an Outperform at LeerinkMarch 17, 2025 | markets.businessinsider.comFavourable Signals For Shattuck Labs: Numerous Insiders Acquired StockMarch 11, 2025 | finance.yahoo.comH.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)February 21, 2025 | markets.businessinsider.comShattuck Labs’ SL-325 shows positive results in inflammatory bowel diseaseFebruary 20, 2025 | markets.businessinsider.comShattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025February 20, 2025 | globenewswire.comShattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in BerlinFebruary 13, 2025 | quiverquant.comShattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025February 13, 2025 | globenewswire.comShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis CongressFebruary 4, 2025 | markets.businessinsider.comShattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn’s and Colitis CongressFebruary 4, 2025 | quiverquant.comShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis CongressFebruary 4, 2025 | globenewswire.comShattuck Labs, Inc. to Present Corporate Update at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | quiverquant.comShattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comShattuck Labs highlights upcoming key milestones in 2025January 3, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTVA, MURA, CNTB, and STTK Company DescriptionsConnect Biopharma NASDAQ:CNTB$0.82 +0.01 (+1.23%) As of 02:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.MetaVia NASDAQ:MTVA$0.78 -0.01 (-1.01%) As of 01:51 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.Mural Oncology NASDAQ:MURA$2.65 +0.04 (+1.53%) As of 02:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Shattuck Labs NASDAQ:STTK$0.84 +0.03 (+4.34%) As of 02:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
